Find a Cancer Program  Log in to MyNetwork
Facebook  LinkedIn  Twitter  ACCC Youtube Channel

Search Drug Alphabetically

Generic Name Pegfilgrastim-cbqv
Brand Name Udenyca®
Payment Category Medicare Part B
Year Introduced 2018
Type of Drug Leukocyte growth factor (pegfilgrastim biosimilar)
Manufacturer Coherus Biosciences
Medical Affairs Questions (date verified) 800.483.3692
Coverage & Reimbursement Questions 844.483.3692
HCPCS Q5111
Billing Unit 0.5 mg
Medicare Payment Limit (Effective July 1, 2019) $359.21

FDA-Approved Indication(s)

  • Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. (3/24/19)

Approved Indication(s) with Orphan Drug Status None
ICD-10 Code(s) for Labeled Indication(s) Agranulocytosis secondary to cancer chemotherapy [D70.1]
Name Strength Form Package Labeler NDC

Copyright © 2019 Association of Community Cancer Centers. All Rights Reserved.
11600 Nebel Street, Suite 201, Rockville, MD 20852  |  Tel.: 301.984.9496  |  Fax: 301.770.1949

CONTACT US